Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).
Karissa M JohnstonLinda HarrisLauren PowellEvan PopoffVladimir CoricGilbert L'ItalienCurtis P SchreiberPublished in: The journal of headache and pain (2022)
ClinicalTrials.gov identifier NCT03266588 .
Keyphrases